Here we evaluated the anticancer actions of combination therapy with HDACIs (Trichostatin A [TSA] or VPA) and anti-cancer agents with anti-angiogenic function (IFNα, rapamycin), and, sought to determine their mechanism of action. Here, IFNA17 is linked to cancer.